Mass spectrometry reveals synergistic effects of nucleotides, lipids, and drugs binding to a multidrug resistance efflux pump

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 24, 2013, Pages 9704-9709

  Marcoux, Julien ^a   Wang, Sheila C ^a   Politis, Argyris ^a   Reading, Eamonn ^a   Ma, Jerome ^b   Biggin, Philip C ^b   Zhou, Min ^a   Tao, Houchao ^c   Zhang, Qinghai ^c   Chang, Geoffrey ^d   Morgner, Nina ^a   Robinson, Carol V ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Mass spectrometry from native state; Real time substrate monitoring

Indexed keywords

AMPHOLYTE; CARDIOLIPIN; CYCLOSPORIN A; DETERGENT; DIACYLGLYCEROL; LIPID; LIPID BINDING PROTEIN; MULTIDRUG RESISTANCE PROTEIN; NUCLEOTIDE;

ARTICLE; BINDING AFFINITY; CALCULATION; CONTROLLED STUDY; DRUG BINDING; DRUG CONFORMATION; DRUG POTENTIATION; DRUG TRANSPORT; GAS; HUMAN; HUMAN CELL; ION MOBILITY SPECTROMETRY; LIGAND BINDING; MASS SPECTROMETRY; MICELLE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PURIFICATION;

MASS SPECTROMETRY FROM NATIVE STATE; REAL TIME SUBSTRATE MONITORING;

BINDING, COMPETITIVE; BIOLOGICAL TRANSPORT; CARDIOLIPINS; CLUSTER ANALYSIS; CYCLOSPORINE; DETERGENTS; DRUG RESISTANCE, MULTIPLE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KINETICS; LIPIDS; MASS SPECTROMETRY; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NUCLEOTIDES; P-GLYCOPROTEIN; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; PROTEIN CONFORMATION;

EID: 84879000440     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1303888110     Document Type: Article

References (47)

1. Darby RA, Callaghan R, McMahon RM (2011) P-glycoprotein inhibition: The past, the present and the future. Curr Drug Metab 12(8):722-731.
2. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5(3):219-234. (Pubitemid 43336035)
3. Sharom FJ, Lu P, Liu R, Yu X (1998) Linear and cyclic peptides as substrates and modulators of P-glycoprotein: Peptide binding and effects on drug transport and accumulation. Biochem J 333(Pt 3):621-630. (Pubitemid 28398529)
4. Sharom FJ (2006) Shedding light on drug transport: Structure and function of the P-glycoprotein multidrug transporter (ABCB1). Biochem Cell Biol 84(6):979-992.
5. Sauna ZE, Ambudkar SV (2007) About a switch: How P-glycoprotein (ABCB1) harnesses the energy of ATP binding and hydrolysis to do mechanical work. Mol Cancer Ther 6(1):13-23. (Pubitemid 46206664)
6. Dey S, Ramachandra M, Pastan I, Gottesman MM, Ambudkar SV (1997) Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci USA 94(20):10594-10599.
7. Lu P, Liu R, Sharom FJ (2001) Drug transport by reconstituted P-glycoprotein in proteoliposomes. Effect of substrates and modulators, and dependence on bilayer phase state. Eur J Biochem 268(6):1687-1697. (Pubitemid 32862703)
8. Aller SG, et al. (2009) Structure of P-glycoprotein reveals a molecular basis for polyspecific drug binding. Science 323(5922):1718-1722.
9. Verhalen B, Ernst S, Börsch M, Wilkens S (2012) Dynamic ligand-induced conformational rearrangements in P-glycoprotein as probed by fluorescence resonance energy transfer spectroscopy. J Biol Chem 287(2):1112-1127.
10. Jin MS, Oldham ML, Zhang Q, Chen J (2012) Crystal structure of the multidrug transporter P-glycoprotein from Caenorhabditis elegans. Nature 490(7421):566-569.
11. Dawson RJP, Locher KP (2006) Structure of a bacterial multidrug ABC transporter. Nature 443(7108):180-185. (Pubitemid 44387602)
12. Ward A, Reyes CL, Yu J, Roth CB, Chang G (2007) Flexibility in the ABC transporter MsbA: Alternating access with a twist. Proc Natl Acad Sci USA 104(48):19005-19010.
13. Sharom FJ (2011) The P-glycoprotein multidrug transporter. Essays Biochem 50(1):161-178.
14. Regev R, Katzir H, Yeheskely-Hayon D, Eytan GD (2007) Modulation of P-glycoprotein-mediated multidrug resistance by acceleration of passive drug permeation across the plasma membrane. FEBS J 274(23):6204-6214. (Pubitemid 350135339)
15. Li-Blatter X, Nervi P, Seelig A (2009) Detergents as intrinsic P-glycoprotein substrates and inhibitors. Biochim Biophys Acta 1788(10):2335-2344.
16. Doige CA, Yu X, Sharom FJ (1993) The effects of lipids and detergents on ATPase-active P-glycoprotein. Biochim Biophys Acta 1146(1):65-72. (Pubitemid 23067043)
17. Clay AT, Sharom FJ (2013) Lipid bilayer properties control membrane partitioning, binding, and transport of p-glycoprotein substrates. Biochemistry 52(2):343-354.
18. Sharom FJ, Yu X, Chu JW, Doige CA (1995) Characterization of the ATPase activity of P-glycoprotein from multidrug-resistant Chinese hamster ovary cells. Biochem J 308(Pt 2):381-390.
19. Barrera NP, Di Bartolo N, Booth PJ, Robinson CV (2008) Micelles protect membrane complexes from solution to vacuum. Science 321(5886):243-246. (Pubitemid 351989094)
20. Velamakanni S, et al. (2009) A multidrug ABC transporter with a taste for salt. PLoS ONE 4(7):e6137.
21. Zhou M, et al. (2011) Mass spectrometry of intact V-type ATPases reveals bound lipids and the effects of nucleotide binding. Science 334(6054):380-385.
22. le Maire M, Champeil P, Moller JV (2000) Interaction of membrane proteins and lipids with solubilizing detergents. Biochim Biophys Acta 1508(1-2):86-111.
23. Romsicki Y, Sharom FJ (1999) The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter. Biochemistry 38(21):6887-6896.
24. Romsicki Y, Sharom FJ (2001) Phospholipid flippase activity of the reconstituted P-glycoprotein multidrug transporter. Biochemistry 40(23):6937-6947. (Pubitemid 32538241)
25. Eckford PD, Sharom FJ (2005) The reconstituted P-glycoprotein multidrug transporter is a flippase for glucosylceramide and other simple glycosphingolipids. Biochem J 389(Pt 2):517-526. (Pubitemid 41021155)
26. Roundhill EA, Burchill SA (2012) Detection and characterisation of multi-drug resistance protein 1 (MRP-1) in human mitochondria. Br J Cancer 106(6):1224-1233.
27. Sharom FJ (2011) Flipping and flopping - Lipids on the move. IUBMB Life 63(9):736-746.
28. Houtkooper RH, Vaz FM (2008) Cardiolipin, the heart of mitochondrial metabolism. Cell Mol Life Sci 65(16):2493-2506.
29. Clemmer DE, Hudgins RR, Jarrold MF (1995) Naked protein conformations: Cytochrome C in the gas phase. J Am Chem Soc 117(40):10141-10142.
30. Gill AC, Jennings KR, Wyttenbach T, Bowers MT (2000) Conformations of biopolymers in the gas phase: A new mass spectrometric method. Int J Mass Spectrom 195(SI):685-697.
31. Ruotolo BT, et al. (2005) Evidence for macromolecular protein rings in the absence of bulk water. Science 310(5754):1658-1661. (Pubitemid 41780783)
32. Loor F, Tiberghien F, Wenandy T, Didier A, Traber R (2002) Cyclosporins: Structureactivity relationships for the inhibition of the human MDR1 P-glycoprotein ABC transporter. J Med Chem 45(21):4598-4612.
33. Kimura Y, Kioka N, Kato H, Matsuo M, Ueda K (2007) Modulation of drug-stimulated ATPase activity of human MDR1/P-glycoprotein by cholesterol. Biochem J 401(2):597-605. (Pubitemid 46166441)
34. Melchior DL, et al. (2012) Determining P-glycoprotein-drug interactions: Evaluation of reconstituted P-glycoprotein in a liposomal system and LLC-MDR1 polarized cell monolayers. J Pharmacol Toxicol Methods 65(2):64-74.
35. Hollenstein K, Dawson RJ, Locher KP (2007) Structure and mechanism of ABC transporter proteins. Curr Opin Struct Biol 17(4):412-418. (Pubitemid 47451766)
36. Seeger MA, van Veen HW (2009) Molecular basis of multidrug transport by ABC transporters. Biochim Biophys Acta 1794(5):725-737.
37. Hänelt I, Wunnicke D, Bordignon E, Steinhoff HJ, Slotboom DJ (2013) Conformational heterogeneity of the aspartate transporter Glt(Ph). Nat Struct Mol Biol 20(2):210-214.
38. Georgieva ER, Borbat PP, Ginter C, Freed JH, Boudker O (2013) Conformational ensemble of the sodium-coupled aspartate transporter. Nat Struct Mol Biol 20(2):215-221.
39. Tao H, et al. (2011) Design and synthesis of Selenazole-containing peptides for cocrystallization with P-glycoprotein. ChemBioChem 12(6):868-873.
40. Eckford PD, Sharom FJ (2008) Interaction of the P-glycoprotein multidrug efflux pump with cholesterol: effects on ATPase activity, drug binding and transport. Biochemistry 47(51):13686-13698.
41. Eckford PD, Sharom FJ (2006) P-glycoprotein (ABCB1) interacts directly with lipid-based anti-cancer drugs and platelet-activating factors. Biochem Cell Biol 84(6):1022-1033. (Pubitemid 46450701)
42. Hernández H, Robinson CV (2007) Determining the stoichiometry and interactions of macromolecular assemblies from mass spectrometry. Nat Protoc 2(3):715-726. (Pubitemid 47040033)
43. Sobott F, Hernández H, McCammon MG, Tito MA, Robinson CV (2002) A tandem mass spectrometer for improved transmission and analysis of large macromolecular assemblies. Anal Chem 74(6):1402-1407. (Pubitemid 34233333)
44. Bush MF, et al. (2010) Collision cross sections of proteins and their complexes: A calibration framework and database for gas-phase structural biology. Anal Chem 82(22):9557-9565.
45. Hall Z, Politis A, Bush MF, Smith LJ, Robinson CV (2012) Charge-state dependent compaction and dissociation of protein complexes: Insights from ion mobility and molecular dynamics. J Am Chem Soc 134(7):3429-3438.
46. Morgner N, Robinson CV (2012) Massign: An assignment strategy for maximizing information from the mass spectra of heterogeneous protein assemblies. Anal Chem 84(6):2939-2948.
47. Van Der Spoel D, et al. (2005) GROMACS: Fast, flexible, and free. J Comput Chem 26(16):1701-1718. (Pubitemid 43076182)